Finkelstein Thompson LLP investigates Darvocet and Darvon Recall

In late 2010, the United States Food and Drug Administration reported receiving clinical data showing the use of Darvocet and Darvon put users "at risk of potentially serious or even fatal heart rhythm abnormalities." In the wake of this information, Darvocet and Darvon were withdrawn from the market by their manufacturer, Xanodyne Pharmaceuticals, Inc. Finkelstein Thompson LLP is investigating potential legal remedies for those affected by this recall, and welcome inquiries from individuals who have purchased or taken these drugs or their generic equivalents.

The affected products (which contain propoxyphene) are used to treat moderate or severe pain. According to the FDA, "even when taken at recommended doses," these drugs cause "significant changes to the electrical activity of the heart." These risks reportedly outweigh any potential benefits from the drugs. Xanodyne has been manufacturing Darvocet and Darvon since 2005, when it purchased the rights to the product from Eli Lilly & Co.

If you or a loved one purchased or used Darvocet, Darvon, or a generic equivalent and you wish to discuss your rights and interests in this matter, please either email us at This email address is being protected from spam bots, you need Javascript enabled to view it .